RAS Mutation Status Confers Prognostic Relevance in Patients Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer.

Zoe Morgan, Bonnie E Chow,Erin A Strong,Susan Tsai,Kathleen Christians,Harveshp Mogal,Thomas Clark Gamblin,Callisia N Clarke

Journal of Surgical Research（2019）

引用 14|浏览9

暂无评分

摘要

RAS mutation is an independent marker of early recurrence in patients undergoing CRS/HIPEC for mCRC and may identify patients who do not derive benefit from this high-risk procedure.

查看译文

关键词

Colorectal cancer,CRS,HIPEC,RAS mutation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要